Search - tctmd.com

Displaying 21 - 40 of 46

Sort: Relevancy | Date

News Conference News ACC 2017

Live From Washington: ACC 2017, Day Three

Shelley Wood

March 19, 2017

News Conference News ACC 2017

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

Todd Neale

March 17, 2017

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

News Opinion Editor's Corner ACC 2016

Hot or Not, This Year’s Trials Offer Food for Thought: My Takeaways From ACC 2016

Shelley Wood

April 13, 2016

News Conference News ACC 2016

Valve Hemodynamic Deterioration Post-TAVR Is Rare, Not Linked With Adverse Cardiovascular Outcomes

Michael O'Riordan

April 07, 2016

News Conference News ACC 2016

Self-Expanding Transcatheter Valve Maintains Advantage Over Surgery at 3 Years in High-Risk Elderly Patients

L.A. McKeown

April 04, 2016

Presentation ACC 2016

Transcatheter or Surgical Aortic Valve Replacement in Intermediate Risk Patients with Aortic Stenosis

Presenter: Craig R. Smith

April 03, 2016

News Conference News ACC 2016

Sapien 3 Superior to Surgery Among Intermediate-Risk Patients in Observational Trial

Yael L. Maxwell

April 03, 2016

News Conference News ACC 2016

TAVR With Sapien XT Noninferior to Surgery in Intermediate-Risk Patients, With a Win for Transfemoral

Shelley Wood

April 02, 2016

News Conference News ACC 2015

ACC-i2 2015: Strategies to Enhance PCI Results, TAVR Highlighted

Todd Neale

March 20, 2015

Presentation ACC 2015

Five-Year Outcomes after Randomization to Transcatheter or Surgical Aortic Valve Replacement: Final Results of The PARTNER 1 Trial

Presenter: Michael J. Mack

March 15, 2015

Presentation ACC 2015

A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis Deemed at Increased Risk for Surgery 2-Year Outcomes

Presenter: Michael J. Reardon

March 15, 2015

News Conference News ACC 2015

Thirty-day Outcomes with Sapien 3 Lowest Seen with Balloon-Expandable TAVR

Yael L. Maxwell

March 15, 2015

News Conference News ACC 2015

Follow-up TAVR Studies Reassure About Valve Durability, Outcomes

Todd Neale

March 15, 2015

News Conference News ACC 2014

ACC/i2 2014: Cardiologists Carefully Consider TAVR, Renal Denervation

Yael L. Maxwell

April 03, 2014

News Conference News ACC 2014

TAV-in-BAV: TAVR Achieves Positive Outcomes In Bicuspid Aortic Valve Disease

Jason Kahn

March 30, 2014

News Conference News ACC 2014

TAVR With the CoreValve Device Superior to Surgery at 1 Year

Yael L. Maxwell

March 29, 2014

Presentation ACC 2013

Three-Year Outcomes after Transcatheter or Surgical Aortic Valve Replacement in High-Risk Patients with Severe Aortic Stenosis

Presenter: Vinod H. Thourani

March 11, 2013

News Conference News ACC 2013

PARTNER: TAVR Still Safe, Effective at 3 Years, Stroke Risk Diminished

Yael L. Maxwell

March 11, 2013

News Conference News ACC 2013

German Valve Registry Shows Advantage of Surgery in Lower Risk Patients

L.A. McKeown

March 11, 2013

Advertisement

Live From Washington: ACC 2017, Day Three

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Hot or Not, This Year’s Trials Offer Food for Thought: My Takeaways From ACC 2016

Valve Hemodynamic Deterioration Post-TAVR Is Rare, Not Linked With Adverse Cardiovascular Outcomes

Self-Expanding Transcatheter Valve Maintains Advantage Over Surgery at 3 Years in High-Risk Elderly Patients

Transcatheter or Surgical Aortic Valve Replacement in Intermediate Risk Patients with Aortic Stenosis

Sapien 3 Superior to Surgery Among Intermediate-Risk Patients in Observational Trial

TAVR With Sapien XT Noninferior to Surgery in Intermediate-Risk Patients, With a Win for Transfemoral

ACC-i2 2015: Strategies to Enhance PCI Results, TAVR Highlighted

Five-Year Outcomes after Randomization to Transcatheter or Surgical Aortic Valve Replacement: Final Results of The PARTNER 1 Trial

A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis Deemed at Increased Risk for Surgery 2-Year Outcomes

Thirty-day Outcomes with Sapien 3 Lowest Seen with Balloon-Expandable TAVR

Follow-up TAVR Studies Reassure About Valve Durability, Outcomes

ACC/i2 2014: Cardiologists Carefully Consider TAVR, Renal Denervation

TAV-in-BAV: TAVR Achieves Positive Outcomes In Bicuspid Aortic Valve Disease

TAVR With the CoreValve Device Superior to Surgery at 1 Year

Three-Year Outcomes after Transcatheter or Surgical Aortic Valve Replacement in High-Risk Patients with Severe Aortic Stenosis

PARTNER: TAVR Still Safe, Effective at 3 Years, Stroke Risk Diminished

German Valve Registry Shows Advantage of Surgery in Lower Risk Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content